213 related articles for article (PubMed ID: 22136267)
1. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response.
Vaisman F; Tala H; Grewal R; Tuttle RM
Thyroid; 2011 Dec; 21(12):1317-22. PubMed ID: 22136267
[TBL] [Abstract][Full Text] [Related]
2. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
[TBL] [Abstract][Full Text] [Related]
3. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
[TBL] [Abstract][Full Text] [Related]
4. Undetectable Thyroglobulin Levels in Poorly Differentiated Thyroid Carcinoma Patients Free of Macroscopic Disease After Initial Treatment: Are They Useful?
Ibrahimpasic T; Ghossein R; Carlson DL; Nixon IJ; Palmer FL; Patel SG; Tuttle RM; Shaha A; Shah JP; Ganly I
Ann Surg Oncol; 2015 Dec; 22(13):4193-7. PubMed ID: 25893415
[TBL] [Abstract][Full Text] [Related]
5. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression.
Lango M; Flieder D; Arrangoiz R; Veloski C; Yu JQ; Li T; Burtness B; Mehra R; Galloway T; Ridge JA
Thyroid; 2013 Sep; 23(9):1099-105. PubMed ID: 23421588
[TBL] [Abstract][Full Text] [Related]
6. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients.
Lamartina L; Montesano T; Trulli F; Attard M; Torlontano M; Bruno R; Meringolo D; Monzani F; Tumino S; Ronga G; Maranghi M; Biffoni M; Filetti S; Durante C
Endocrine; 2016 Nov; 54(2):467-475. PubMed ID: 26668060
[TBL] [Abstract][Full Text] [Related]
7. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
[TBL] [Abstract][Full Text] [Related]
8. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer.
Padovani RP; Robenshtok E; Brokhin M; Tuttle RM
Thyroid; 2012 Aug; 22(8):778-83. PubMed ID: 22780333
[TBL] [Abstract][Full Text] [Related]
9. Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients' Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial.
Jammah AA; Masood A; Akkielah LA; Alhaddad S; Alhaddad MA; Alharbi M; Alguwaihes A; Alzahrani S
Front Endocrinol (Lausanne); 2020; 11():603432. PubMed ID: 33716951
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma.
Clayman GL; Agarwal G; Edeiken BS; Waguespack SG; Roberts DB; Sherman SI
Thyroid; 2011 Dec; 21(12):1309-16. PubMed ID: 22136266
[TBL] [Abstract][Full Text] [Related]
11. Preablative Stimulated Thyroglobulin Correlates to New Therapy Response System in Differentiated Thyroid Cancer.
Yang X; Liang J; Li T; Zhao T; Lin Y
J Clin Endocrinol Metab; 2016 Mar; 101(3):1307-13. PubMed ID: 26789779
[TBL] [Abstract][Full Text] [Related]
12. Disease Progression in Papillary Thyroid Cancer with Biochemical Incomplete Response to Initial Therapy.
Zern NK; Clifton-Bligh R; Gill AJ; Aniss A; Sidhu S; Delbridge L; Learoyd D; Robinson B; Sywak M
Ann Surg Oncol; 2017 Sep; 24(9):2611-2616. PubMed ID: 28585075
[TBL] [Abstract][Full Text] [Related]
13. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.
Kim TY; Kim WB; Kim ES; Ryu JS; Yeo JS; Kim SC; Hong SJ; Shong YK
J Clin Endocrinol Metab; 2005 Mar; 90(3):1440-5. PubMed ID: 15613412
[TBL] [Abstract][Full Text] [Related]
14. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
[TBL] [Abstract][Full Text] [Related]
15. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.
Tuttle RM; Tala H; Shah J; Leboeuf R; Ghossein R; Gonen M; Brokhin M; Omry G; Fagin JA; Shaha A
Thyroid; 2010 Dec; 20(12):1341-9. PubMed ID: 21034228
[TBL] [Abstract][Full Text] [Related]
16. Incidence and implications of negative serum thyroglobulin but positive I-131 whole-body scans in patients with well-differentiated thyroid cancer prepared with rhTSH or thyroid hormone withdrawal.
Cherk MH; Francis P; Topliss DJ; Bailey M; Kalff V
Clin Endocrinol (Oxf); 2012 May; 76(5):734-40. PubMed ID: 22050475
[TBL] [Abstract][Full Text] [Related]
17. Possible reasons for different pattern disappearance of thyroglobulin and thyroid peroxidase autoantibodies in patients with differentiated thyroid carcinoma following total thyroidectomy and iodine-131 ablation.
Thomas D; Liakos V; Vassiliou E; Hatzimarkou F; Tsatsoulis A; Kaldrimides P
J Endocrinol Invest; 2007 Mar; 30(3):173-80. PubMed ID: 17505148
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy.
Vaisman F; Momesso D; Bulzico DA; Pessoa CH; Dias F; Corbo R; Vaisman M; Tuttle RM
Clin Endocrinol (Oxf); 2012 Jul; 77(1):132-8. PubMed ID: 22248037
[TBL] [Abstract][Full Text] [Related]
19. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.
Park S; Kim WG; Song E; Oh HS; Kim M; Kwon H; Jeon MJ; Kim TY; Shong YK; Kim WB
Thyroid; 2017 Apr; 27(4):524-530. PubMed ID: 27869547
[TBL] [Abstract][Full Text] [Related]
20. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
Stevic I; Dembinski TC; Pathak KA; Leslie WD
Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
